Dacarbazine and Interferon for Melanoma Treatment
Author Information
Author(s): N.H. Mulder, P.H.B. Willemse, H. Schraffordt Koops, E.G.E. de Vries, D.Th. Sleijfer
Primary Institution: University Hospital Groningen
Hypothesis
Combining dacarbazine and interferon alpha 2a will improve treatment outcomes for patients with disseminated malignant melanoma.
Conclusion
The combination of dacarbazine and interferon alpha 2a resulted in a response rate of 35% in patients with disseminated malignant melanoma.
Supporting Evidence
- The response rate of the combination treatment was 35%.
- Complete responses lasted for 16+, 7, and 5+ months.
- Nineteen patients had progressive disease, while 11 had a response.
Takeaway
Doctors tested a new treatment for skin cancer using two medicines together, and about one in three patients got better.
Methodology
Patients received a combination of daily interferon and intravenous dacarbazine over several treatment courses, with evaluations for response and toxicity.
Limitations
The study had a small sample size and excluded patients with central nervous system metastasis.
Participant Demographics
18 male and 13 female patients, median age 51 years (range 17-74).
Statistical Information
Confidence Interval
95% confidence interval 19-55%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website